



February 08, 2024

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Dear Sir/Madam,

Subject : **Investor Presentation**

Stock Code : **BSE – 539787, NSE – HCG**

Reference : **Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”)**

We wish to inform you that the Board of Directors of the Company, at their meeting held on February 08, 2024, *inter alia*, has approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2023 (“Financial Results”).

In this respect, we enclose herewith the Presentation on the Financial Results of the Company for the quarter and nine months ended December 31, 2023.

This is also available on the website of the Company www.hcgoncology.com.

Kindly take the intimation on record.

Thanking you,

For **HealthCare Global Enterprises Limited**

Sunu Manuel
Company Secretary & Compliance Officer

Encl: a/a.



HEALTHCARE GLOBAL ENTERPRISES LIMITED



INVESTOR PRESENTATION
February 2024



SAFE HARBOR



This presentation and its contents are confidential and are not for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from the United States of America, Canada, Australia, Japan or any jurisdiction where such distribution is unlawful.

This presentation has been prepared by **HealthCare Global Enterprises Limited (the "Company")**. These materials are not for publication or distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). These materials are not an offer of securities for sale into the United States, Canada or Japan or any other jurisdiction. Any securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of any securities of the Company is being made in the United States.

The information contained in this presentation is for information purposes only and does not constitute or form part of an offer or invitation for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract, commitment or investment decision in relation thereto in India, the United States or any other jurisdiction.

No person accepts any liability whatsoever for any loss howsoever arising from the use of this document or of its contents or otherwise arising in connection therewith. The information set out herein may be subject to updating, completion, revision, verification and amendment without notice and such information may change materially. Financial information contained in this presentation has been derived from the restated consolidated and standalone financial statements of the Company and have been rounded off to the next integer, except percentages which have been rounded off to one decimal point.

This presentation contains certain "forward looking statements". Forward-looking statements are based on certain assumptions and expectations of future events. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. Although the Company believes that such forward-looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met. Neither the Company nor any of its advisors or representatives assumes any responsibility to update forward-looking statements or to adapt them to future events or developments.

This presentation includes certain industry data and projections that have been obtained from industry publications and surveys. Industry publications and surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance that the information is accurate or complete. Neither the Company nor any of its advisors or representatives have independently verified any of the data from third-party sources or ascertained the underlying economic assumptions relied upon therein. No representation or claim is made that the results or projections contained in this presentation will actually be achieved. All industry data and projections contained in this presentation are based on data obtained from the sources cited and involve significant elements of subjective judgment and analysis, which may or may not be correct. For the reasons mentioned above, you should not rely in any way on any of the projections contained in this presentation for any purpose. No responsibility or liability whatsoever is undertaken for the contents hereof.

This presentation is based on information regarding the Company and the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither the Company nor its advisors or representatives are under an obligation to update, revise or affirm.





SUBASENI LENKA, CANCER WINNER

“ I am eternally thankful to Dr. Panda and other specialists at HCG Panda Cancer Hospital, as the specialists were able to treat my condition the right way, the first time ”

Q3 & 9MFY24 FINANCIAL & OPERATIONAL HIGHLIGHTS



Clinical Highlights & Recognitions

Latest Publications

- ❖ **Shaurya Verma** : Lymph node level ratio: Are we relying too much on numbers?
- ❖ **Raj Nagarkar** : Lingual Artery as the Recipient Vessel of Choice in Patients Requiring a Second or Third Free Flap in Recurrent Oral Cancers and Vessel-Depleted Neck: A 5-Year Experience in a Single Institute
- ❖ **Gururaj Arakeri** : Evaluation of fluoride levels in areca nut, tobacco, and commercial smokeless tobacco products: a pilot study
- ❖ **Pratik Shah** : Global Burden of Cardiovascular Diseases and Risks, 1990-2022
- ❖ **Shekhar Patil** : Survival of Trial-Like and Non-Trial-Like Patients With Immunotherapy in Advanced Hepatocellular Carcinoma in Real World: A Collaborative Multicenter Indian Study (IMHEP)
- ❖ **Shyam Srivastava** : Correlation of Hematological Parameters With Clinical Outcomes in Cervical Cancer Patients Treated With Radical Radio(chemo)therapy: A Retrospective Study
- ❖ **Bharat Prajapati** : Practice Patterns and Survival in Patients with Resected Pancreatic Ductal Adenocarcinomas (PDAC) - Results from the Multicentre Indian Pancreatic & Periampullary Adenocarcinoma Project (MIPPAP) Study

Smart APP – HCG Care

- ❖ > 56K digital outpatient advices
- ❖ > 300 Consultants active on the digital platform
- ❖ Diagnosis & Staging based on international coding guidelines
- ❖ CIMS drug interaction alerts incorporated into digital advices
- ❖ Multidisciplinary clinic module



Our CSR Initiatives – World Cancer Day 2024




Campaign	Power Of Good Wishes - A Collective Beacon of Hope		
Goal	Create a repository of positive wishes from strangers for cancer warriors.		
Objectives	Raise awareness about cancer and the HCG brand by engaging the general population. Empower individuals to become cancer advocates through meaningful interactions.		
Internal	Organized activities for cancer patients under the banner of Power of Good Wishes. Invited external participants such as survivors and caregivers to share positive wishes	External	Collaborated with radio stations for campaign amplification and created a Vox Pop video. Strangers were asked to share wishes for cancer warriors
		Extensions	LinkedIn Activation – Power of Good Wishes with HCG Leadership. Shared the collected wishes with the cancer warriors and capture their reactions.






Financial Highlights Q3 FY24


REVENUE




REVENUE - HCG Centers⁽¹⁾




REVENUE - Milann Centers




ADJUSTED EBITDA*




ADJUSTED EBITDA MARGIN*



PROFIT AFTER TAX (Pre-IND AS)



PROFIT AFTER TAX (Post-IND AS)



*Adjusted EBITDA excludes ESOP; ESOP for Q3FY24 is Rs 17.7 mn, for Q3FY23 is Rs 17.9 mn


^ Excludes One-time M&A cost of Rs 11.7 mn & Sale of Asset of Rs 10.2 mn

1. 22 comprehensive cancer centers, 3 multispecialty hospitals




Financial Highlights 9M FY24


REVENUE




REVENUE - HCG Centers⁽¹⁾




REVENUE - Milann Centers




ADJUSTED EBITDA*




ADJUSTED EBITDA MARGIN*



PROFIT AFTER TAX (Pre-IND AS)



PROFIT AFTER TAX (Post-IND AS)



*Adjusted EBITDA excludes ESOP; ESOP for Q9MFY24 is Rs 57.4 mn, for 9MFY23 is Rs 49.5 mn


[^] Excludes One-time M&A cost of Rs 11.7 mn & Sale of Asset of Rs 10.2 mn

1. 22 comprehensive cancer centers, 3 multispecialty hospitals




Improved Performance Leading to Profitability


Revenue
(INR mn)




EBITDA (Excl. ESOP)
(INR mn)



PAT
(INR mn)
(Post IND-AS 116)



PAT
(INR mn)
(Pre IND-AS 116)



(1) Includes loss due to exceptional items of INR 847 mn
(2) Includes gain on exceptional items of INR 1,401 mn


*Excludes One-time M&A cost of Rs 11.7 mn & Sale of Asset of Rs 10.2 mn



Growth Across HCG Centers


Matured Centers

~1.3x growth in last 9 quarters




Emerging Centers

~1.5x growth in last 9 quarters




Matured Centers

~1.2x growth in last 9 quarters



Emerging Centers

~1.7x growth in last 9 quarters



Revenues for matured centers were impacted on account of:

- Reduced our scope of services in one of the hospitals in Bangalore housed in a Trust run Medical College resulting in reduction of **Revenue by ~ 80 Mn and EBITDA by ~15 Mn.**
- HCG has **scaled down or exited all shop in shop model under its network.**
- Planning State of Art, **100 bed stand-alone facility in the nearby location** in North Bangalore; **Expected to be launched in next 15-18 months.**
- Our Cyclotron business got impacted due to flood in Chennai, **resulting in loss of INR 18 Mn revenue and INR 13 Mn EBITDA**

**Excl. Corporate Expenses,



Strong Operating Metrics with Significant Capacity Headroom



Key Driver	Metric Indicator	% Revenue	Q3'23	Q3'24	9M'23	9M'24
OPD Footfall ('000)	Lead indicator of Volume Growth ; key operating metric tracked by HCG; has correlation to OPD Footfalls	18%*	91	110	274	306
Chemo Sessions Administered ('000)	Key indicator for Medical Oncology ; procedures are primarily day care oriented with no capacity constraint	40%	34	36	100	109
LINAC - Capacity Utilization	Key indicator for Radiation Oncology ; Addition of 4 new LINAC's during the year	19%	66%	61%	67%	63%
In Patient Bed Occupancy #	Indicator for Surgical Oncology ; with decreasing ALOS and flexibility to add balance non-operational capacity beds, not a capacity constraint operationally ; additional 195 beds available to be made operational	23%	60%	52%	61%	57%

*Revenue % for out-patient and others only



HCG – Q3FY24 Operational Metrics[#]



TOTAL AOR (%)

59.8%

65.7% in Q3FY23

↓ 590 bps

MATURED CENTERS AOR (%)

59.3%

63.2% in Q3FY23

↓ 390 bps

EMERGING CENTERS AOR^{^*} (%)

61.0%

71.9% in Q3FY23

↓ 1,090 bps

MATURED CENTERS ROCE (%)

18.5%

18.9% in Q3FY23

↓ 40 bps

ROCE pre-corporate allocations stands at 22.5%

TOTAL ARPOB (Rs.)

42,788

37,014 in Q3FY23

↑ 15.6%

MATURED CENTERS ARPOB (Rs.)

43,669

40,154 in Q3FY23

↑ 8.6%

EMERGING CENTERS ARPOB[^] (Rs.)

40,545

30,058 in Q3FY23

↑ 34.9%

EMERGING CENTERS[^] ROCE (%)

-3.9%

-5.8% in Q3FY23

↑ 190 bps

ROCE pre-corporate allocations stands at -0.8%

[^]Emerging Center represents centers operational after 2017
^{*}89% of the capacity beds are operational; AOR 56% on capacity beds
[#]Excl. Fertility



HCG – Cluster Wise Revenue Break Up

CLUSTER	Q3FY24	Q3FY23	Y-o-Y	9MFY24	9MFY23	Y-o-Y
KARNATAKA*	1,422.9	1,395.8	2%	4,500.5	4,193.3	7%
GUJARAT	1,174.8	1,025.3	15%	3,526.2	3,079.0	15%
MAHARASHTRA	727.8	615.7	18%	2,099.5	1,780.6	18%
EAST INDIA	532.6	419.7	27%	1,554.3	1,208.6	29%
ANDHRA PRADESH	349.8	318.4	10%	1,033.4	915.1	13%
TAMIL NADU	63.3	77.6	-18%	219.7	205.0	7%
NORTH INDIA	218.9	200.4	9%	617.4	581.1	6%
AFRICA	44.5	26.9	65%	119.5	58.1	106%
TOTAL	4,534.8	4,079.8	11%	13,670.6	12,020.7	14%

NAGPUR

KOLKATA

RANCHI

Mumbai

VIZAG

59% Y-o-Y

For Q3FY24

57% Y-o-Y

For Q3FY24

31% Y-o-Y

For Q3FY24

17% Y-o-Y

For Q3FY24

19% Y-o-Y

For Q3FY24


*Impact on account of reduction in scope of services from the last Shop in Shop model that we operated in Bangalore. Revenue growth for Karnataka excl. this is ~8% for Q3FY24 & 8.4% for 9MFY24



Milann – Implementing Strategic Initiatives

Particulars	Q3FY24	Q3FY23	Growth Y-o-Y	9MFY24	9MFY23	Growth Y-o-Y
New Registrations	1,011	1,215	-16.8%	3,488	3,979	-12.3%
IVF Cycles	381	464	-17.9%	1,260	1,475	-14.6%
Revenues (Rs. Mn.)	164	167	-1.8%	504	505	-0.2%

BENGALURU (5 Centers)



Focus on market leadership in Bangalore

NORTH INDIA



Discontinuation of non-profitable assets in Delhi

1. Centers in operation prior to April 1, 2016, i.e., Shivananda, JP Nagar and Indiranagar



Capital Expenditure & Net Debt

CAPITAL EXPENDITURE (Rs. Mn.)

HCG CENTERS	9MFY24	FY23
Matured Centers	1,100	1,094
Emerging Centers	79	163
TOTAL CAPEX	1,179	1,257

NET DEBT (Rs. Mn.)

NET DEBT	31 st Dec 2023	30 th Sept 2023
Bank Debt ⁽¹⁾	4,615	3,798
Vendor Finance ⁽²⁾	318	320
Other Debt	38	36
Less: Cash & Cash Equivalents ⁽³⁾	1,298	1,053
NET DEBT	3,672	3,102
Capital Leases: Ind AS116	5,593	5,123
Net Debt (Incl. Leases)	9,265	8,225

ONGOING CAPEX (Rs. Mn.)

Sr. No	Particulars	Capex incurred till 31 st December 2023	Expected Capex for rest of FY24	Total Planned Capex	Expected date of Operations
1	Ahmedabad – Phase II	483	417	1,070	Q1 FY25
2	Whitefield (Extension of Bangalore - COE)	34	15	250	Q1 FY26

1. Bank debt: Net of Bank balance held as margin money of INR 73.25 Mn and investment in fixed deposits of INR 591.77 Mn (Margin money value reclassified to other deposit) as of 30th Dec -23, INR 147 Mn and investment in fixed deposits of INR 351.82 Mn as of 30th Sep -23. The unamortized portion of processing fees amounting to INR 34.41 Mn as on 30th Dec -23 & INR 33.92 Mn as on 30th Sep -23 netted off against Bank Debt

2. Vendor Finance; Includes Forex reinstatement of INR 14.13 Mn as of 31st Dec 2023 and INR 4.05 Mn as of 30th Sep-23

3. Cash and cash equivalents: Includes investment in mutual funds of INR 18.59 Mn as at 31st Dec 2023 and INR 17.83 Mn as at 30th Sep 23



Q3 & 9MFY24 Consolidated Profit & Loss Account

Profit and Loss (in Rs. Mn.)	Q3 FY24	Q3 FY23	Y-o-Y	Q2 FY24	Q-o-Q	9M FY24	9M FY23	Y-o-Y
Revenues from Operations	4,689.5	4,239.1		4,859.6		14,146.2	12,504.3	
Income from Govt. Grant	9.2	7.7		9.8		28.7	23.0	
Total Revenue from Operations	4,698.7	4,246.8	10.6%	4,869.4	-3.5%	14,174.9	12,527.3	13.2%
Cost of Goods Sold	1,139.2	1,075.1		1,208.6		3,526.9	3,076.7	
Employee Cost	755.6	674.3		753.5		2,256.5	2,013.1	
Medical Consultancy Charges	1,043.0	883.6		1,062.8		3,079.6	2,648.2	
Other Expenses	935.1	840.8		980.1		2,857.0	2516.2	
EBITDA Excluding ESOPS	825.8	773.0	6.8%	864.4	-4.5%	2,454.9	2,273.1	8.0%
EBITDA Excluding ESOPS (%)	17.6%	18.2%	-63 bps	17.8%	-18 bps	17.3%	18.1%	-83 bps
One-time Expense	21.9	0.0		0.0		21.9	0.0	
ESOP's	17.7	17.9		18.1		57.4	49.5	
Reported EBIDTA	786.2	755.1	4.1%	846.3	-7.1%	2,375.6	2,223.6	6.8%
Reported EBITDA Margin (%)	16.7%	17.8%	-104 bps	17.4%	-64 bps	16.8%	17.8%	-100 bps
Depreciation	441.6	407.7		432.1		1,283.8	1,212.7	
Other Income	60.7	36.5		34.0		118.9	85.3	
EBIT	405.3	383.9	5.6%	448.2	-9.6%	1,210.7	1,096.2	10.4%
Finance Cost	294.6	270.8		268.9		819.0	778.7	
Share in Profit/(loss) in JV and Associates	-0.1	-0.1		-0.1		3.3	-0.1	
Profit before Tax	110.6	113.0	-2.1%	179.2	-38.3%	395.0	317.4	24.4%
Taxes & Minority Interest	53.6	37.6		43.5		126.2	107.7	
Profit After Tax	57.0	75.4	-24.4%	135.7	-58.0%	268.8	209.7	28.2%
PAT Margin (%)	1.2%	1.8%	-56 bps	2.8%	-157 bps	1.9%	1.7%	22 bps
EPS	0.4	0.5		1.0		1.9	1.5	



SHANKAR, CANCER WINNER

“ The days I was at HCG,
I felt like I was sleeping at
home. They never stop caring
for you. The doctors and
nurses are always finding ways
to make this difficult journey
as comfortable as possible ”

HISTORICAL FINANCIAL HIGHLIGHTS



Historical Profit & Loss Account

Profit and Loss (in Rs. Mn.)	FY23	FY22	FY21	FY20	FY19	CAGR
Revenues from Operations	16,914	13,948	10,092	10,923	9,760	
Income from Govt. Grant	30	30	43	33	27	
Total Revenue from Operations	16,944	13,978	10,134	10,956	9,787	15%
Costs of Goods Sold	4,241	3,549	3,632	3,645	3,581	
Employee Cost	2,687	2,337	1,959	2,080	1,845	
Medical Consultancy Charges	3,561	2,958	2,218	2,451	2,114	
Other Expenses	3,248	2,754	2,289	2,305	2,389	
EBITDA	3,208	2,380	1,266	1,722	1,252	24%
EBITDA Margin (%)	18.9%	17.0%	12.5%	15.7%	12.8%	
Depreciation	1,635	1,583	1,592	1,485	851	
Other Income	132	127	170	70	74	
EBIT	1,484	924	-157	307	475	32%
Finance Cost	1,035	978	1,192	1,377	699	
Extraordinary Items	-	946	-847	-	-	
Share in Profit/(loss) in JV and Associates	-	-14	-4	-123	-110	
Profit before Tax	449	878	-2,199	-1,193	-334	NA
Taxes, Other Comprehensive Income & Minority Interest	155	340	-264	-131	-86	
Profit After Tax	293	538	-1,935	-1,062	-248	NA
PAT Margin (%)	1.7%	3.8%	-19.1%	-9.7%	-2.5%	
EPS (in INR)	0	4.1	-16.9	-2.9	-2.8	



Historical Balance Sheet

Balance Sheet - Equity & Liabilities (in Rs. Mn.)	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19
Equity Share Capital	1,391	1,390	1,254	887	879
Other Equity	7,214	7,313	5,718	2,926	3,933
Equity Attributable To Equity Holders Of The Company	8,605	8,703	6,972	3,813	4,811
Non-Controlling Interests	89	134	168	385	619
Total Equity	8,694	8,837	7,140	4,198	5,430
Non-Current Liabilities					
Financial Liabilities	0	0	0	0	0
Borrowings	3,628	3,629	3,462	5,296	4,666
Lease Liabilities	4,531	4,659	4,693	6,092	202
Other Financial Liabilities	0	255	0	624	0
Provisions	132	105	86	73	56
Other Non-Current Liabilities	359	0.0	280	422	318
Deferred Tax Liabilities (Net)	124	13	43	70	43
Total Non-Current Liabilities	8,774	8,661	8,564	12,576	5,285
Current Liabilities					
Financial Liabilities	0	0	0	0	0
Borrowings	365	448	670	937	648
Lease Liabilities	488	411	365	215	0.0
Trade Payables	0	0	0	0	0
Total Outstanding Dues Of Micro Enterprises And Small Enterprises	50	20	3	0	0.0
Total Outstanding Dues Of Creditors Other Than Micro Enterprises And Small Enterprises	2,435	1,919	1,452	1,536	1,683
Other Financial Liabilities	1,404	936	1,428	2,654	2,557
Other Current Liabilities	755	785	626	305	337
Provisions	171	173	104	91	63
Income Tax Liabilities (Net)	25	5	4	22	12
Total Current Liabilities	5,693	4,698	4,653	5,758	5,300
Total Equity And Liabilities	23,160	22,195	20,356	22,532	16,015



Historical Balance Sheet

Balance Sheet - Assets (in Rs. Mn.)	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19
Non-Current Assets					
Property, Plant And Equipment	9,718	9,315	8,531	9,271	8,026
Capital Work in Progress	182	217	300	461	1,440
Rights-of-use Assets	3,813	4,045	4,114	5,776	0
Goodwill	1,812	1,813	963	1,093	1,093
Other Intangible Assets	187	298	215	320	96
Intangible Assets Under Development		30	206	268	469
Financial Assets		0	0	0	0
Investments	97	58	57	74	68
Loans Receivable	0	0	451	516	476
Other Financial Assets	543	546	168	222	196
Deferred Tax Assets (Net)	53	60	343	261	311
Income Tax Assets (Net)	574	459	426	818	307
Other Non-Current Assets	378	331	232	414	742
Total Non-Current Assets	17,357	17,172	16,007	19,494	13,222
Current Assets		0	0	0	0
Inventories	383	300	211	233	285
Financial Assets		0	0	0	0
Trade Receivables	3,025	2,175	1,866	1,857	1,646
Cash And Cash Equivalents	1,746	1,975	300	318	280
Bank Balances Other Than Cash And Cash Equivalents	219	0	109	3	44
Loans	18	16	93	54	40
Other Financial Assets	74	341	1,546	275	211
Other Current Assets	339	217	225	300	288
Total Current Assets	5,803	5,024	4,350	3,038	2,793
Total Assets	23,160	22,195	20,356	22,532	16,015



Historical Cash Flow Statement

Cash Flow Statement (in Rs. Mn)	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19
Net Profit Before Tax	449	878	-2,287	-1,193	-334
Adjustments For: Non - Cash Items / Other Investment Or Financial Items	2,753	1,666	3,619	2,988	2,463
Operating Profit Before Working Capital Changes	3,201	2,543	1,333	1,795	2,130
Changes In Working Capital	-459	-105	-507	-226	-774
Cash Generated From Operations	2,743	2,438	826	1,569	1,355
Direct Taxes Paid (Net Of Refund)	-227	-237	380	-267	370
Net Cash From Operating Activities	2,516	2,201	1,205	1,301	985
Net Cash From Investing Activities	-1,330	1,246	-1,711	-1,014	-2,382
Net Cash From Financing Activities	-1,401	-1,549	1,123	-584	835
Net Increase/Decrease In Cash And Cash Equivalents	-215	1,898	617	-297	-562
Add: Cash & Cash Equivalents At The Beginning Of The Period	1,927	29	-588	-291	271
Cash & Cash Equivalents At The End Of The Period	1,712	1,927	29	-588	-291



THANK YOU

Company: HealthCare Global Enterprises Limited



CIN: L15200KA1998PLC023489

For updates and specific queries, please visit
www.hcgoncology.com
or feel free to contact investors@hcgoncology.com

Investor Relation Advisors: Strategic Growth Advisors

SGA Strategic Growth Advisors

CIN: U74140MH2010PTC204285

Mr. Sagar Shroff / Mr. Ayush Haria
sagar.shroff@sgapl.net / ayush.harria@sgapl.net
Tel: +91 98205 19303 / +91 98204 62966

© 2022 HealthCare Global Enterprises Limited., All Rights Reserved.

HCG Logo is trademark of HealthCare Global Enterprises Limited. In addition to Company data, data from market research agencies, Stock Exchanges and industry publications has been used for this presentation.

This material was used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners.